期刊文献+

MRI MnDPDP增强对原发性肝细胞癌的诊断价值 被引量:3

Diagnostic Value of MnDPDP Enhanced MRI in Primary Hepatocellular Carcinoma
下载PDF
导出
摘要 目的 :评估MRIMnDPDP增强不同延迟时间成像对原发性肝细胞癌的诊断价值。材料和方法 :对 3 6例HCCs行MRIMnDPDP增强研究。静脉滴注MnDPDP结束后 5min开始每隔 5min成像 1次 ,直至 40min ;第二天行延迟 2 4h成像。成像序列为SET1WI和FMPSPGRT1WI。对不同延迟时间图像的信噪比 (S/N)、对比度噪声比 (C/N)及病灶显示率进行比较研究。结果 :(1)不同延迟时间图像的S/N无统计学差异。 (2 ) 5~ 2 5min图像肝与HCC之间C/N高于 3 0min以后图像 (P<0 0 5 )。 (3 )病灶显示率和定性率均以延迟 2 4h最高 (92 7% ) ,但各组图像之间无显著差异。结论 :MnDPDP增强MRI的HCC显示率和定性率均以延迟 2 Purpose: To evaluate the diagnostic value of MnDPDP enhanced MRI at different delayed times for primary hepatocellular carcinoma (HCC). Materials and Medthods: Thirty six patients of HCCs were investigated with MnDPDP enhanced MRI. The images were performed at every five minutes until 40 minutes after the end of intravenous infusion of MnDPDP, and the 24 hour delayed images were obtained the next day. The imaging sequences were T 1WI SE and T 1WI FMPSPGR. The S/N, C/N and the lesion detectability were compared for the images on the basis of delayed times. Results: (1) The S/N±S was not equal to each other according to the delayed times, but there was no statistical significance existed among them; (2)The C/N±S of the postcontrast images at 5~25 min were higher than that at and after 30 min (P<0 05); (3) The highest detection rate and charactersisation of HCCs were reached at 24 hour delayed images. Conclusion: The 24 hour delayed image of MRI enhanced with MnDPDP were the best one for detection and characterisation of HCCs.
出处 《中国医学影像学杂志》 CSCD 2002年第1期1-4,共4页 Chinese Journal of Medical Imaging
关键词 MRI 显示率 原发性肝细胞癌 HCC 诊断价值 病灶 成像 图像 延迟 噪声比 primary hepatocellular carcinoma manganese dipyridoxyl diphosphate (Manganese trisodium) magnetic resonance imaging contrast agent delayed imaging time
  • 相关文献

参考文献8

  • 1Wang C, Gordon PB, Hustvedt SO, et al. MR imaging properties and phar-macokinetics of MnDPDP in healthy volunteers. Acta Radiologica, 1997,38:665
  • 2Wang C. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonanceimaging of the liver and pancreas. Acta Radiologica, 1998, 39:7
  • 3Rummeuy EJ, Torres CG, Kurdziel JC, et al. MnDPDP for MR imaging of the liver: results of independent image evaluation of the European phase Ⅲstudies. Acta Radiologica, 1997, 38:638
  • 4Jung G, Heindel W, Krahe T, et al. Influence of the hepatobiliary contrastagent mangafodipir trisodium (MnDPDP) on the imaging properties of the abdominal organ. Magn Reson Imaging, 1998, 16(8):925
  • 5Toft KG, Kindberg GM and Skotland T, et al. Mangafodipir trisodium injec-tion, a new contrast medium for magnetic rsonance imaging. In vitro metaboliem and protien binding studies of the active component MnDPDP in human blood. J Pharm Biomed Anal, 1997,15:983
  • 6Toft KG, Hustvedt SO, Grant D, et al. Metabolism of mangafodipir trisodium (MnDPDP), a new contrast medium for magnetic resonance imaging, in beagle dogs. Eur J Drug Mtab Pharmacokinet, 1997, 22:65
  • 7Hanhn PF, and Saini S. Liver-specific MR imaging contrast agents. Radol Clini Nor Am, 1998, 36:287
  • 8Murakami T, Baron RL, Peterson MS, et al. Hepatocellular carcinoma: MR imaging with m angafodipir trisodium (MnDPDP). Radiology, 1996, 2000:69

同被引文献25

  • 1汤钊猷.现代肿瘤学[M].上海:上海医科大学出版社,1992.272.
  • 2[3]Low RN,Francis IR,Sigeti JS,et al.Abdominal MR imaging: comparison of T2-weighted fast and conventional spin-echo,and contrast-enhanced fast multiplanar spoiled gradient-recalled imaging.Radiology,1993,186:803
  • 3[4]Whiteney WS,Herfken RJ,Jeffrey RB,et al.Dynamic breath-hold multiplanar spoiled gradient-recalled MR imaging with Gadolinium-enhancement for differentiating hepatic hemangiomas from malignancies at 1.5T.Radiology,1993,189:863
  • 4[5]Fujita T,Ito K,Honjo K,et al.Detection of hepatocellular carcinoma: comparison of T2-weighted breath-hold fast spin-echo sequences and high-resolution dynamic MR imaging with a phased-array body coil.J Magn Reson Imaging,1999,9:274
  • 5[7]Toft KG,Hustvedt SO,et al.Metabolism and pharmacokinetics of Mn-DPDP in man.Acta Radiologica,1997,38:677
  • 6[8]Hannhn PF and Saini S.Liver-specific MR imaging contrast agents.Radiol Clini Nor Am,1998,36:287
  • 7[9]Kirchin MA,Pirovano GP,Spinazzi A.Gadobenate dimeglumine (Gd-BOPTA): an overview.Invest Radiol,1998,33:798
  • 8[10]Spinazzi A,Lorusso V,Pirovano G,et al.Safety,tolerance,biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers.Acad Radiol,1999,6:282
  • 9[11]Kirchin MA,Pirovano G,Venetianer C,et al.Safety assessment of gadobenate dimeglumine (Multihance): extended clinical experience from phase Ⅰ studies to post-marketing surveillance.J Magn Reson Imaging,2001,14:281
  • 10[12]Lorusso V,Arbughi T,Tirone P,et al.Pharmacokinetics and tissue distribution in animals of gadobenate ion,the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance).J Comput Assist Tomogr,1999,1:181

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部